AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...

AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...

AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...